Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024 ...
Dr Melanie Ivarsson was on Monday named chief executive of the Health Data Research Service (HDRS), which will give ...
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...
In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...
Oct 29 (Reuters) - Moderna Inc (MRNA.O), opens new tab on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the ...
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
WASHINGTON -- Moderna submitted its application to the U.S. Food and Drug Administration for emergency use authorization of its updated COVID-19 vaccine booster for use in people age 18 and older, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback